查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1939557

人工生物瓣膜市场：依组织材料、植入方法、瓣膜位置和最终用户划分，全球预测，2026-2032年

Artificial Biological Valve Market by Tissue Material, Implantation Method, Valve Position, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，人工生物瓣膜市场价值将达到 83 亿美元，到 2026 年将成长至 87.2 亿美元，到 2032 年将达到 119.3 亿美元，复合年增长率为 5.32%。

主要市场统计数据
基准年 2025 83亿美元
预计年份：2026年 87.2亿美元
预测年份：2032年 119.3亿美元
复合年增长率 (%) 5.32%

这份精闢的概述定义了生物瓣膜治疗的未来，清楚地阐述了临床需求、材料创新和策略决策驱动因素。

人工生物瓣膜市场正处于转折点，其驱动因素包括临床需求的整合、技术创新以及治疗管道的演变。本执行摘要整合了多学科的洞见，旨在帮助临床医生、製造商、支付方和投资者了解影响瓣膜选择、部署方式和生命週期管理的关键因素。本概要并非着重于原始数据，而是聚焦于结构性驱动因素、营运影响以及已被证明在不同医疗体系中最有效的策略因应措施。

全面审视材料科学的突破、製程创新以及不断变化的法规环境如何重新定义瓣膜治疗的临床途径和商业性价值

组织瓣膜领域正经历变革时期，这场变革超越了产品性能的渐进式改进，从根本上改变了瓣膜的研发、选择和交付方式。组织处理和保存技术的进步降低了瓣膜的即时免疫抗原性，延长了其功能寿命；而新型抗钙化化学方法和基质稳定技术则改变了人们对瓣膜长期性能的预期。同时，成像技术、计算建模和器械尺寸设计的改进使得手术全期规划更加精准，併发症率降低，从而促进了微创手术方式的普及。

基于证据的分析，探讨2025年关税调整如何重塑生物瓣膜采购、生产在地化和临床采购的动态。

2025年实施的新关税对组织瓣膜领域的供应链、筹资策略和定价结构产生了连锁反应。在贸易层面，进口组织加工材料和成品组织瓣膜组件关税的提高增加了到岸成本，迫使许多製造商重新评估其筹资策略。因此，采购团队转向更多元化的供应商基础，并在可能的情况下进行近岸外包；而临床团队则加强了与供应商的合作，以稳定前置作业时间并确保服务承诺。

一种将组织基质、手术通道、解剖目标和临床环境与产品设计和市场策略要求联繫起来的多层分割观点

了解市场区隔对于解读生物瓣膜市场的需求驱动因素和创新重点至关重要。从组织材料、植入方法、瓣膜位置和最终用户等多层次观点，可以揭示产品设计和商业化的不同需求。同种异体移植和异质骨移植之间组织材料的差异造就了不同的研发路径。冷冻保存或去细胞的同种异体移植强调免疫相容性和维持天然几何形状，而含有牛或猪基质的异质骨移植则优先考虑可扩展性和标准化处理通讯协定。这些材料选择会对手术流程产生影响，因为保存的人体组织和可持续来源的动物源性瓣膜叶片在组织处理、储存要求和术中表现方面存在差异。

对全球医疗保健系统中阀门创新推广规模的影响，进行区域性评估，包括采纳、报销和生产策略。

区域趋势将影响组织瓣膜技术创新成果的采纳、报销和支持。对美洲、欧洲、中东和非洲以及亚太地区的比较观点突显了各地区的机会和挑战。在美洲，临床系统优先考虑手术流程和治疗结果的透明度，而整合医疗网络则优先考虑能够缩短住院时间和降低再入院风险的技术。该地区的医生和管理人员越来越倾向于为合适的患者群体选择经导管解决方案，而外科中心则继续投资于支持混合治疗途径的先进瓣膜保留技术。

对製造规模、精准创新和伙伴关係主导的临床检验如何构成成功瓣膜公司核心竞争优势的策略性回顾

组织瓣膜领域的竞争动态反映了现有企业在扩大生产规模和临床支援方面与新兴企业在组织处理、输送系统和病患选择工具方面不断创新之间的平衡。那些投资于垂直整合生产、广泛的临床培训网络和完善的监管资源的市场领导，受益于与医院系统和支付方建立的稳固关係。这些企业往往专注于在耐用性、稳健的供应链和全面的服务方面进行渐进式改进，从而减轻医疗服务提供者的手术全期负担。

一项切实可行的策略议程，整合了製造韧性、流程优化和循证商业化，旨在加速技术应用并降低营运风险。

产业领导者应采取多管齐下的策略方法，将科学进步转化为永续的优势。首先，应优先考虑采购和生产的韧性，具体措施包括扩大区域加工能力、建立检验的合作伙伴网络，以及投资模组化製造，以便在需求波动时能够灵活切换自体移植和异质骨移植的加工。其次，应使产品开发与外科手术趋势保持一致，优化瓣膜结构，使其既适用于外科手术也适用于经导管输送，确保提高耐久性的同时不会影响输送性能或抗压合性能。

我们采用透明、多方面的调查方法，结合面对面的专家访谈、临床文献综述和比较过程分析，以确保获得基于证据的见解。

本简报的研究结合了多种定性和定量方法，旨在对生物瓣膜动力学提供全面、可靠的三角观点。主要研究包括对心臟外科医生、介入性心臟病专家、采购主管和监管专家进行结构化访谈，以收集第一线营运洞察和采购决策依据。此外，还与製造和供应链主管进行了深入讨论，以了解产能限制、认证週期和关税政策变化带来的实际影响。

一份简洁、全面的分析报告，重点阐述了技术创新、临床证据和营运灵活性如何共同决定实施的成功和长期价值。

本执行摘要阐述了正在转型中的行业现状：材料科学的进步、手术流程偏好的转变以及政策的调整相互交织，共同重塑着商业和临床决策。组织处理技术和器械介面设计的持续创新正在重塑人们对长期性能的预期，而经导管和微创治疗途径的出现则扩大了患者覆盖范围，并改变了医院的工作流程。同时，贸易政策和关税趋势凸显了区域製造和供应链柔软性的策略价值，促使企业重新调整资本和筹资策略。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第3章执行摘要

  • CXO观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新たな商机
  • 次世代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • ポーターの五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第5章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESGとサステナビリティ分析
  • ディスラプションとリスクシナリオ
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按组织材料分類的人工生物瓣膜市场

  • 同种移植弁
    • 冷冻保存
    • 去细胞化
  • 异质骨移植
    • 牛源
    • ブタ由来

9. 依植入方式分類的人工生物瓣膜市场

  • 外科
    • 微创
    • 开胸置换术
  • 经导管
    • 经主动脉
    • 顶端
    • 经股动脉

第十章 按瓣膜位置分類的人工生物瓣膜市场

  • 主动脉瓣
  • 二尖瓣
  • 肺动脉瓣
  • 三尖瓣

第十一章 按最终用户分類的人工生物瓣膜市场

  • 门诊手术中心
  • 医院
  • 专科诊所

第十二章 区域性生物人工瓣膜市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 按组别分類的人工生物瓣膜市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国人工生物瓣膜市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 美国生物人工瓣膜市场

第十六章：中国人工生物瓣膜市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Artivion, Inc.
  • Boston Scientific Corporation
  • Braile Biomedica
  • Colibri Heart Valve
  • Corcym
  • Edwards Lifesciences
  • Foldax, Inc.
  • Jenavalve Technology, Inc.
  • Labcor Laboratorios Ltda
  • Lepu Medical Technology Co., Ltd.
  • LifeNet Health
  • LivaNova PLC
  • Medtronic plc
  • TTK Healthcare Limited
Product Code: MRR-9A6A6F297853

The Artificial Biological Valve Market was valued at USD 8.30 billion in 2025 and is projected to grow to USD 8.72 billion in 2026, with a CAGR of 5.32%, reaching USD 11.93 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.30 billion
Estimated Year [2026] USD 8.72 billion
Forecast Year [2032] USD 11.93 billion
CAGR (%) 5.32%

An incisive overview framing clinical imperatives, material innovations, and strategic decision drivers that define the future trajectory of biological valve care

The artificial biological valve landscape is at an inflection point driven by converging clinical demands, technological innovation, and evolving care pathways. This executive summary synthesizes cross-disciplinary insights so that clinicians, manufacturers, payers, and investors can understand the forces reshaping valve selection, deployment approaches, and lifecycle management. Rather than present raw figures, the narrative focuses on structural drivers, operational implications, and the strategic responses that are proving most effective across diverse healthcare systems.

As pressure on cardiovascular services intensifies, decision-makers require actionable synthesis that bridges bench science and bedside realities. This introduction establishes the analytical frame: an emphasis on material science developments, procedural modality shifts, regulatory and reimbursement dynamics, and the interplay between supply chain resilience and clinical adoption. With those dimensions in view, subsequent sections examine transformative shifts, tariff-related disruptions in the United States, segmentation nuances, regional patterns, competitive behavior, recommended courses of action for industry leaders, and the methodological approach undergirding the research.

Taken together, this introduction positions the reader to interpret downstream analysis with a clear understanding of scope, purpose, and the practical lenses applied. The goal is to enable immediate application of insights to strategic planning, product development prioritization, and stakeholder engagement initiatives.

A comprehensive look at how material science breakthroughs, procedural innovation, and regulatory shifts are redefining clinical pathways and commercial value in valve therapy

The biological valve sector is undergoing transformative shifts that extend beyond incremental product improvements and into fundamental changes in how valves are developed, selected, and delivered. Advances in tissue processing and preservation have reduced time-zero immunogenicity and extended functional durability, while novel anti-calcification chemistries and matrix-stabilizing techniques are changing expectations for long-term performance. Concurrently, improvements in imaging, computational modeling, and device sizing have enabled tighter peri-procedural planning and lower complication rates, catalyzing wider acceptance of less invasive approaches.

At the same time, procedural innovation has redefined clinical pathways. Transcatheter techniques, refined delivery systems, and procedural standardization have lowered thresholds for intervention among older and higher-risk populations. This shift is reshaping the interplay between surgical teams and interventional cardiology, influencing hospital workflows and perioperative resource allocation. In parallel, supply chain modernization-driven by on-demand manufacturing capabilities, stronger cold-chain logistics, and regional sourcing strategies-has improved reliability but introduced new complexity in supplier qualification and regulatory oversight.

Regulatory bodies are responding to these changes with more adaptive approval pathways and a greater emphasis on real-world evidence collection, influencing post-market surveillance obligations and data infrastructure investments. Financial stakeholders are increasingly focused on reimbursement alignment with procedural outcomes and total cost of care, prompting manufacturers to offer outcome-linked contracts and extended support programs. Taken together, these transformative shifts create an environment where speed-to-clinic, clinical evidence generation, and integrated service models determine competitive advantage.

An evidence-based analysis of how 2025 tariff changes reshaped procurement, manufacturing localization, and clinical purchasing dynamics for biological valves

The imposition of new tariffs in the United States during 2025 has a cumulative effect that ripples across supply chains, procurement strategies, and pricing structures in the biological valve sector. At the transactional level, increased duties on imported tissue-processing supplies and finished bioprosthetic components elevated landed costs and forced many manufacturers to re-evaluate sourcing strategies. As a result, procurement teams have shifted toward more diversified supplier bases and nearshoring where feasible, while clinical teams have engaged more intensely with vendors to stabilize lead-times and service commitments.

Over time, these tariff-driven cost pressures amplified the importance of manufacturing scale, vertical integration, and regional production capacity. Organizations with in-region processing facilities or captive supply chains experienced fewer operational disruptions, while those dependent on distant suppliers confronted longer qualification cycles and greater inventory buffers. Consequently, capital allocation decisions increasingly prioritized resilient manufacturing footprints and multi-sourcing arrangements over marginal product enhancements.

Clinically, the tariffs influenced device selection dialogues within purchasing committees and hospital formularies, where the total cost of implant and associated peri-procedural expenses were scrutinized more closely. Payers and health systems sought stronger value propositions, prompting manufacturers to expand service offerings, warranty terms, and post-procedural outcome support. Finally, the tariffs accelerated collaboration between industry and regulators to clarify classification and duty treatment for advanced tissue technologies, underscoring that trade policy can be a persistent determinant of operational strategy and long-term competitiveness.

A layered segmentation perspective connecting tissue substrates, procedural routes, anatomical targets, and care settings to product design and market strategy imperatives

Understanding segmentation is central to interpreting demand drivers and innovation priorities in the biological valve market, and a layered view across tissue material, implantation method, valve position, and end user reveals distinct imperatives for product design and commercialization. Tissue material distinctions between homograft and xenograft create divergent development paths: homograft options, whether cryopreserved or decellularized, emphasize immunologic compatibility and native geometry preservation, while xenograft pathways, including bovine and porcine substrates, prioritize scalability and standardized processing protocols. These material choices have procedural consequences because tissue handling, storage requirements, and intraoperative behavior differ between preserved human tissues and sustainably sourced animal-derived leaflets.

Implantation method further refines competitive positioning. Surgical approaches, both minimally invasive and open replacement, demand designs optimized for suture techniques, hemostasis, and intraoperative adaptability, whereas transcatheter modalities-across transaortic, transapical, and transfemoral routes-require low-profile delivery systems, crimping resilience, and rapid deployment reliability. Valve position matters as well, with aortic implants facing distinct hemodynamic stresses and durability expectations compared with mitral, pulmonary, and tricuspid applications, each presenting bespoke anchoring and sealing challenges. Finally, end users-ranging from ambulatory surgery centers to hospitals and specialized clinics-exert differential requirements for logistics, training, and post-operative follow-up, influencing packaging, on-site technical support, and educational investments by manufacturers.

Taken together, these segmentation layers produce overlaying constraints and opportunities: product teams must balance tissue biology with mechanical demands, clinicians must select modalities aligned with institutional capabilities, and commercial leaders must map go-to-market approaches to the specific needs of ambulatory centers, high-throughput hospitals, or niche specialty clinics.

A regionally differentiated assessment of adoption, reimbursement, and manufacturing strategies that influence how valve innovations scale across global healthcare systems

Regional dynamics shape how innovations in biological valve technology are adopted, reimbursed, and supported, and a tripartite lens across the Americas, Europe, Middle East & Africa, and Asia-Pacific clarifies distinct opportunities and constraints. In the Americas, clinical systems emphasize procedural throughput and outcome transparency, with integrated health networks prioritizing technologies that reduce length of stay and readmission risk. Physicians and administrators in this region increasingly favor transcatheter solutions for appropriate patient cohorts, while surgical centers continue to invest in advanced valve preservation techniques that support hybrid procedural pathways.

Across Europe, Middle East & Africa, regulatory harmonization and diverse payer models create a mosaic of adoption timelines, where centralized HTA bodies and regional reimbursement policies influence procurement cadence. Healthcare delivery in various jurisdictions values long-term durability and robust clinical evidence, prompting manufacturers to generate region-specific real-world data and engage closely with hospital systems to align value demonstrations with national purchasing priorities. Meanwhile, in the Asia-Pacific region, rapid capacity expansion, growing cardiology specialization, and significant investments in domestic manufacturing have accelerated both surgical and transcatheter uptake. Local production capabilities and evolving regulatory frameworks in several countries encourage partnerships and technology transfer arrangements to meet regional demand while addressing cost sensitivity.

These regional characteristics underscore that global strategies must be adapted: supply chain planning, clinical engagement models, and evidence-generation efforts should be tailored to the procurement norms, clinical capabilities, and policymaker expectations that vary across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

A strategic review of how manufacturing scale, targeted innovation, and partnership-driven clinical validation form the competitive core of successful valve enterprises

Competitive dynamics in the biological valve arena reflect a balance between incumbents scaling manufacturing and clinical support, and emerging challengers introducing discrete innovations in tissue processing, delivery systems, and patient selection tools. Market leaders that have invested in vertically integrated production, extensive clinical training networks, and broad regulatory dossiers benefit from established relationships with hospital systems and payers. These organizations tend to focus on incremental improvements in durability, supply chain robustness, and bundled service offerings that reduce peri-procedural complexity for care providers.

At the same time, nimble entrants and specialist developers are differentiating through targeted innovation: advanced decellularization platforms, proprietary anti-calcification chemistries, and delivery systems engineered for specific anatomical positions. Such firms often leverage partnerships with academic centers to accelerate clinical validation and use strategic collaborations to access distribution channels. Intellectual property around processing techniques and device interface design is a key asset, and portfolio diversification-spanning homograft processing services, xenograft leaflets, and transcatheter delivery platforms-improves resilience against single-product risk.

Investors and strategic buyers are attracted to companies that can demonstrate clinical differentiation, regulatory readiness, and the operational capacity to scale. As a result, merger and acquisition activity, licensing agreements, and co-development partnerships remain central to competitive playbooks. The overall strategic implication is clear: organizational success increasingly depends on integrating clinical evidence generation, robust manufacturing, and tailored commercial models that align with provider and payer expectations.

Actionable strategic imperatives combining manufacturing resilience, procedural optimization, and evidence-led commercialization to accelerate adoption and reduce operational risk

Industry leaders must adopt a multi-dimensional playbook to convert scientific advances into sustainable advantage. First, prioritize resilience in sourcing and production by expanding regional processing capacity, pursuing validated partner networks, and investing in modular manufacturing that can switch between homograft and xenograft processing when demand profiles shift. Second, align product development with procedural trends by optimizing valve constructs for both surgical and transcatheter delivery, ensuring that durability gains do not compromise deliverability or crimping resilience.

Third, deepen clinical partnerships to generate real-world evidence that supports reimbursement conversations and informs iterative product improvements. Establishing post-market registries and pragmatic outcome studies enables rapid feedback loops between clinicians and design teams and strengthens value propositions to payers. Fourth, adopt differentiated commercial models that reflect the needs of ambulatory surgery centers, high-volume hospitals, and specialized clinics; bundled service agreements, outcome-linked pricing, and on-site training programs can materially influence purchasing decisions and procedural adoption.

Finally, embed regulatory strategy and health economics early in development to reduce approval timelines and demonstrate comparative value. Proactive engagement with regulatory bodies and payer advisory panels will clarify evidence expectations and can streamline post-approval obligations. Taken together, these actions will help organizations reduce operational risk, accelerate adoption, and maintain alignment with evolving clinical practice.

A transparent, multi-method research approach combining primary expert interviews, clinical literature review, and comparative process analysis to ensure evidence-based insights

The research underpinning this summary combines multiple qualitative and quantitative approaches to ensure a robust, triangulated perspective on biological valve dynamics. Primary research included structured interviews with cardiac surgeons, interventional cardiologists, procurement leaders, and regulatory specialists to capture frontline operational insights and procurement rationales. These conversations were complemented by in-depth consultations with manufacturing and supply chain executives to understand capacity constraints, qualification cycles, and the practical implications of tariff policy changes.

Secondary sources comprised peer-reviewed clinical literature, regulatory guidance documents, patent filings, device labeling, and publicly available clinical registries, which were used to validate procedural trends and device performance claims. Where appropriate, anonymized case studies illustrating adoption patterns and hospital decision-making were synthesized to contextualize strategic recommendations. Data quality assurance included cross-validation of interview findings against documented clinical outcomes and triangulation across multiple independent sources to reduce bias.

Analytical techniques involved thematic coding of qualitative inputs, scenario-based impact assessment for policy shifts, and comparative process mapping to highlight friction points across implantation methods and end-user settings. The methodology emphasizes transparency, replicability, and pragmatic orientation, focusing on actionable insight generation rather than speculative forecasting.

A concise synthesis underscoring how technical innovation, clinical evidence, and operational agility together determine successful adoption and long-term value

This executive synthesis highlights a sector in transition where material science advancements, evolving procedural preference, and policy shifts intersect to redefine commercial and clinical decision-making. Durable innovation in tissue processing and device interface design is reshaping expectations for long-term performance, while transcatheter and minimally invasive pathways are expanding the pool of treatable patients and altering hospital workflows. Concurrently, trade policy and tariff developments have emphasized the strategic value of regional manufacturing and supply chain flexibility, prompting reprioritization of capital and procurement strategies.

For stakeholders across the value chain, the imperative is to integrate clinical evidence generation, manufacturing resilience, and tailored commercial models into a cohesive strategy. Organizations that combine technical differentiation with strong clinical partnerships and adaptive go-to-market approaches will be best positioned to capture emerging opportunities and mitigate operational risks. Ultimately, the combination of rigorous clinical validation, operational agility, and close alignment with care providers and payers will determine which innovations achieve durable adoption and deliver measurable improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Biological Valve Market, by Tissue Material

  • 8.1. Homograft
    • 8.1.1. Cryopreserved
    • 8.1.2. Decellularized
  • 8.2. Xenograft
    • 8.2.1. Bovine
    • 8.2.2. Porcine

9. Artificial Biological Valve Market, by Implantation Method

  • 9.1. Surgical
    • 9.1.1. Minimally Invasive
    • 9.1.2. Open Replacement
  • 9.2. Transcatheter
    • 9.2.1. Transaortic
    • 9.2.2. Transapical
    • 9.2.3. Transfemoral

10. Artificial Biological Valve Market, by Valve Position

  • 10.1. Aortic
  • 10.2. Mitral
  • 10.3. Pulmonary
  • 10.4. Tricuspid

11. Artificial Biological Valve Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Hospitals
  • 11.3. Specialized Clinics

12. Artificial Biological Valve Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Artificial Biological Valve Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Artificial Biological Valve Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Artificial Biological Valve Market

16. China Artificial Biological Valve Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Artivion, Inc.
  • 17.7. Boston Scientific Corporation
  • 17.8. Braile Biomedica
  • 17.9. Colibri Heart Valve
  • 17.10. Corcym
  • 17.11. Edwards Lifesciences
  • 17.12. Foldax, Inc.
  • 17.13. Jenavalve Technology, Inc.
  • 17.14. Labcor Laboratorios Ltda
  • 17.15. Lepu Medical Technology Co., Ltd.
  • 17.16. LifeNet Health
  • 17.17. LivaNova PLC
  • 17.18. Medtronic plc
  • 17.19. TTK Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY CRYOPRESERVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY CRYOPRESERVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY CRYOPRESERVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY DECELLULARIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY DECELLULARIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY DECELLULARIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY BOVINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY BOVINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY BOVINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY PORCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY PORCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY PORCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY OPEN REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY OPEN REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY OPEN REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSAORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSAORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSAORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSAPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSAPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSAPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSFEMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSFEMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSFEMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY MITRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY MITRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY MITRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY PULMONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY PULMONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY PULMONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRICUSPID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRICUSPID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRICUSPID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 182. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 191. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 192. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 193. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 194. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TISSUE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY HOMOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY XENOGRAFT, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY VALVE POSITION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA ARTIFICIAL BIOLOGICAL VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)